The immunogenicity of therapeutic proteins and the Fabry antibody standardization initiative

被引：12
作者：
Schellekens, Huub [1 ]
机构：
[1] Univ Utrecht, Dept Pharmaceut Sci, Dept Innovat Studies, NL-3508 TB Utrecht, Netherlands
来源：
CLINICAL THERAPEUTICS | 2008年 / 30卷
关键词：
D O I：
10.1016/S0149-2918(08)80041-0
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
[No abstract available]
引用
收藏
页码：S50 / S51
页数：2
相关论文
共 6 条
[1]   Structure-immunogenicity relationships of therapeutic proteins [J].
Hermeling, S ;
Crommelin, DJA ;
Schellekens, H ;
Jiskoot, W .
PHARMACEUTICAL RESEARCH, 2004, 21 (06) :897-903
[2]   Inhibitor development in hemophiliacs: The roles of genetic versus environmental factors [J].
Lee, Christine A. ;
Lillicrap, David ;
Astermark, Jan .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2006, 32 :10-14
[3]   Thrombocytopenia caused by the development of antibodies to thrombopoietin [J].
Li, JZ ;
Yang, C ;
Xia, YP ;
Bertino, A ;
Glaspy, J ;
Roberts, M ;
Kuter, DJ .
BLOOD, 2001, 98 (12) :3241-3248
[4]   Immunogenicity of therapeutic proteins: Clinical implications and future prospects [J].
Schellekens, H .
CLINICAL THERAPEUTICS, 2002, 24 (11) :1720-1740
[5]  
Schellekens H, 2003, Dev Biol (Basel), V112, P23
[6]   Bioequivalence and the immunogenicity of biopharmaceuticals [J].
Schellekens, H .
NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (06) :457-462
1